William Tsai, DO
Family Medicine · Upland, CANPI 1285620443
Payments from drug & device makers
Across 325 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$903
- Pfizer$674
- Lilly USA, LLC$618
- Novartis$513
- Sanofi-aventis U.S. LLC$487
- Boehringer Ingelheim$354
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,26898%
- Education$1052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $903 |
| Pfizer | 31 | $674 |
| Lilly USA, LLC | 28 | $618 |
| Novartis | 30 | $513 |
| Sanofi-aventis U.S. LLC | 37 | $487 |
| Boehringer Ingelheim | 16 | $354 |
| Johnson & Johnson | 28 | $338 |
| Astellas Pharma US Inc | 14 | $298 |
| Amgen | 15 | $293 |
| Inari Medical, Inc. | 1 | $177 |
| AstraZeneca | 9 | $163 |
| Amarin Pharma, Inc. | 6 | $144 |
| Merck | 7 | $141 |
| Teva Pharmaceuticals USA, Inc. | 4 | $133 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $122 |
| Otsuka America Pharmaceutical, Inc. | 5 | $117 |
| Shield Therapeutics Inc | 4 | $89 |
| Bayer | 3 | $82 |
| Kowa Pharmaceuticals America, Inc. | 3 | $82 |
| Exact Sciences | 4 | $80 |
| Sunovion Pharmaceuticals Inc. | 6 | $73 |
| GSK | 3 | $56 |
| AbbVie(2 entities) | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Corcept Therapeutics | 1 | $37 |
| Mannkind Corporation | 2 | $34 |
| Eisai Inc. | 2 | $33 |
| Edwards Lifesciences | 1 | $28 |
| Avanos Medical | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $27 |
| Insmed, Inc. | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Lundbeck LLC | 1 | $18 |
| MDD US Operations, LLC | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,373 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 158 | $153,843 |
| OzempicSemaglutide | 91 | $129,757 |
| ProliaDenosumab | 47 | $79,084 |
| FarxigaDapagliflozin Propanediol | 77 | $74,455 |
| EliquisApixaban | 66 | $54,689 |
| XareltoRivaroxaban | 40 | $46,248 |
| JanuviaSitagliptin Phosphate | 33 | $40,163 |
| MyrbetriqMirabegron | 55 | $37,249 |
| Sevelamer Hcl | 28 | $30,020 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $26,393 |
| EntrestoSacubitril/Valsartan | 12 | $18,259 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $16,286 |
| ZenpepLipase/Protease/Amylase | 22 | $15,130 |
| LokelmaSodium Zirconium Cyclosilicate | 23 | $14,879 |
| InvokanaCanagliflozin | 13 | $14,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $354 | $160,457171 claims |
| Novo NordiskOzempic | $903 | $129,75791 claims |
| AstraZenecaFarxiga, Lokelma | $163 | $89,334100 claims |
| AmgenProlia | $293 | $79,08447 claims |
| Johnson & JohnsonXarelto, Invokana | $338 | $60,76153 claims |
| MerckJanuvia, Janumet | $141 | $56,44954 claims |
| PfizerEliquis | $674 | $54,68966 claims |
| Astellas Pharma US IncMyrbetriq | $298 | $37,24955 claims |
| NovartisEntresto | $513 | $18,25912 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $117 | $6,97712 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $82 | $3,36611 claims |
| AbbVieLumigan | $41 | $2,73811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Upland
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.